Various PSMA-targeting radioligands have been developed and three of them have been approved by the US FDA: [18F]DCFPyL and [68Ga]Ga-PSMA-11 for prostate cancer imaging [4,5] and [177Lu]Lu-PSMA-617 for prostate cancer radioligand therapy [6]. Here, FOLH1 is linked to prostate carcinoma.